Table 1. Clinicopathological characteristics of patients with recurrence according to lymph node status (N=493).
| Variables | n (%) | P | ||
| Total | pN0 | pN+ | ||
| IQR, interquartile range. | ||||
Age at recurrence (year) (
)
|
63.5±11.7 | 65.2±13.9 | 63.3±11.5 | 0.295 |
| Gender | 0.470 | |||
| Male | 370 (75.1) | 35 (79.5) | 335 (74.6) | |
| Female | 123 (24.9) | 9 (20.5) | 114 (25.4) | |
| Differentiation | 0.051 | |||
| Well/moderate | 180 (36.5) | 22 (50.0) | 158 (35.2) | |
| Poorly/signet ring cell | 313 (63.5) | 22 (50.0) | 291 (64.8) | |
| T stage | <0.001 | |||
| T1 | 17 (3.4) | 11 (25.0) | 6 (1.3) | |
| T2 | 23 (4.7) | 3 (6.8) | 20 (4.5) | |
| T3 | 175 (35.5) | 21 (47.7) | 154 (34.3) | |
| T4a | 278 (56.4) | 9 (20.5) | 269 (59.9) | |
| N stage | − | |||
| N0 | 44 (8.9) | 44 (100) | − | |
| N1 | 45 (9.1) | − | 45 (10.0) | |
| N2 | 93 (18.9) | − | 93 (20.7) | |
| N3a | 176 (35.7) | − | 176 (39.2) | |
| N3b | 135 (27.4) | − | 135 (30.1) | |
Tumor size (mm) (
)
|
58.3±24.0 | 43.5±30.9 | 59.8±22.7 | <0.001 |
| Tumor location | 0.497 | |||
| Lower | 180 (36.5) | 16 (36.4) | 164 (36.5) | |
| Middle | 110 (22.3) | 7 (15.9) | 103 (22.9) | |
| Upper | 116 (23.5) | 10 (22.7) | 106 (23.6) | |
| Mixed | 87 (17.6) | 11 (25.0) | 76 (16.9) | |
| Lymphovascular invasion | 0.075 | |||
| No | 285 (57.8) | 31 (70.5) | 254 (56.6) | |
| Yes | 208 (42.2) | 13 (29.5) | 195 (43.4) | |
| Neural invasion | 0.281 | |||
| No | 346 (70.2) | 34 (77.3) | 312 (69.5) | |
| Yes | 147 (29.8) | 10 (22.7) | 137 (30.5) | |
| Adjuvant chemotherapy | <0.001 | |||
| No | 132 (26.8) | 22 (50.0) | 110 (24.5) | |
| Yes | 361 (73.2) | 22 (50.0) | 339 (75.5) | |
| Time to recurrence (month) [median (IQR)] | 16 (9−28) | 26 (14−41) | 15 (9−27) | 0.001 |
| Symptom(s) of recurrence | 0.304 | |||
| Asymptomatic | 146 (29.6) | 16 (36.4) | 130 (29.0) | |
| Symptomatic | 347 (70.4) | 28 (63.6) | 319 (71.0) | |
| Number of metastasis site(s) | 0.552 | |||
| 1 site | 339 (68.8) | 32 (72.7) | 307 (68.4) | |
| ≥2 sites | 154 (31.2) | 12 (27.3) | 142 (31.6) | |
| Treatment of recurrence | 0.215 | |||
| Support treatment only | 150 (30.4) | 17 (38.6) | 133 (29.6) | |
| Potential curative treatment | 343 (69.6) | 27 (61.4) | 316 (70.4) | |